Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia.

Item

http://www.wikidata.org/entity/Q38100787

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Safety and efficacy of ofatumu ...... chronic lymphocytic leukaemia.

@en

type

Item

label

Safety and efficacy of ofatumu ...... chronic lymphocytic leukaemia.

@en

prefLabel

Safety and efficacy of ofatumu ...... chronic lymphocytic leukaemia.

@en

P1476

Safety and efficacy of ofatumu ...... chronic lymphocytic leukaemia.

@en

P2093

Martin J S Dyer

http://www.w3.org/2001/XMLSchema#string

P2860

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

CD20 deficiency in humans results in impaired T cell-independent antibody responses

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness

Inactivating mutations of acetyltransferase genes in B-cell lymphoma

Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.

Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells.

P304

199-207

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2040620712445329

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236255399

http://www.w3.org/2001/XMLSchema#string

P698

23606931

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

lymphocyte

P932

3627333

http://www.w3.org/2001/XMLSchema#string